Advertisement
Record quarterly highlights include:
Other quarterly highlights include:
Quarterly Results: For the fiscal quarter ended December 31, 2009, Abaxis reported revenues of $31.0 million, as compared with revenues of $27.0 million for the comparable period last year, an increase of 15 percent. Revenues from instrument sales, which include chemistry analyzers, hematology instruments, coagulation analyzers and i-STAT analyzers, increased by an aggregate of $485,000, or 6 percent, over the same period last year. The company reported total medical and veterinary instrument sales of 1,212 units, up 37 percent over the same period last year. Revenues from consumables, which include reagent discs, hematology reagent kits, coagulation cartridges, i-STAT cartridges and heartworm rapid tests, increased by an aggregate of $3.4 million, or 20 percent, over the same period last year. The company reported net income of $3.4 million for the fiscal quarter ended December 31, 2009, which was flat in comparison to the same period in 2008. The company's effective tax rate in the quarter ended December 31, 2009 was 37 percent, compared to 34 percent for the same period last year. The company reported diluted net income per share of $0.15 (calculated based on 22,617,000 shares) for the third quarter of fiscal 2010, compared to $0.15 per share (calculated based on 22,264,000 shares) for the same period last year.
Advertisement
Nine-Month Results: For the nine-month period ended December 31, 2009, Abaxis reported revenues of $90.9 million, as compared with revenues of $79.2 million for the comparable period last year, an increase of 15 percent. Revenues from instrument sales decreased by an aggregate of $1.4 million, or 6 percent, over the same period last year. The company reported total medical and veterinary instrument sales of 2,971 units, up 23 percent over the same period last year. Revenues from consumables increased by an aggregate of $11.6 million, or 23 percent, over the same period last year. The company reported net income of $10.4 million, compared to $9.4 million for the same period last year. The company's effective tax rate in the nine-month period ended December 31, 2009, was 39 percent, compared to 36 percent for the same period last year. The company reported diluted net income per share of $0.46 (calculated based on 22,549,000 shares) for the nine months ended December 31, 2009, compared to $0.42 per share (calculated based on 22,325,000 shares) for the same period last year.
Other Reported Information: Consumables revenues for the third quarter of fiscal 2010 were $20.1 million, up 20 percent over the $16.8 million reported for the same period last year. Total sales in the medical market for the third quarter of fiscal 2010 were $5.2 million, a decrease of 28 percent compared to the same period last year, primarily due to a decrease in instrument sales to the U.S. government and distributors in North America. Medical sales worldwide, excluding sales to the U.S. government, during the third quarter of fiscal 2010 were $4.8 million, a decrease of 21 percent compared to the same period last year, primarily due to inventory stock adjustments by distributors in North America. Total sales in the veterinary market for the third quarter of fiscal 2010 were $23.9 million, an increase of 33 percent compared to the same period last year. Veterinary reagent disc sales for the third quarter of fiscal 2010 were $12.8 million, an increase of 13 percent compared to the same period last year.
Non-cash compensation expense recognized for share-based awards during the third quarter of fiscal 2010 was $1.4 million, compared to $465,000 for last year's comparable quarter.
Clint Severson, chairman and chief executive officer of Abaxis, commented, "We are pleased to report another solid quarter of double digit growth accompanied with strong operating margins. Revenues grew 15% to a record of $31.0 million for the quarter, led by a 37% increase in instrument unit sales. Operationally, gross margins continue at record levels, expanding 300 basis points versus the comparable quarter last year. Our balance sheet remains healthy with $93.2 million in cash, cash equivalents, short- and long-term investments and no long-term debt."
Mr. Severson continued, "Our medical market sales team has made substantial progress in expanding our customer base by growing the installed base of Piccolo instruments, excluding the U.S. government. With Piccolo instrument unit sales during the third quarter increasing 12% compared to our second quarter and 48% higher than the first quarter of the fiscal year, we are beginning to experience the benefits of our new strategic plan in addressing the medical point-of-care market. Our goal is to remain focused on growing both our medical and veterinary markets by providing leading-edge technology and quality products to our customers allowing them to improve the way healthcare is delivered."
Conference Call
Abaxis has scheduled a conference call to discuss its results at 4:15 p.m. Eastern Time on Thursday, January 28, 2010. Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com. A replay of the call is available by visiting http://www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, access code 437292, through February 1, 2010. This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at http://www.sec.gov.
About Abaxis
Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.
Use of Non-GAAP Financial Measures
To supplement the financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share. This non-GAAP financial presentation is not a measurement of performance under GAAP in the United States of America. Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.
This press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance of new or planned product offerings, process improvements and product manufacturing quality and efficiencies in future production of our products. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to the market acceptance of the company's products and the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the company's intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy, risks involved in carrying of inventory and other risks detailed under "Risk Factors" in Abaxis' Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2009 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Financial Tables on Following Pages
-- Revenues of $31.0 million, up 15% over last year's comparable quarter. -- North America revenues of $24.9 million, up 9% over last year's comparable quarter. -- Veterinary market sales of $23.9 million, up 33% over last year's comparable quarter. -- Total medical and veterinary instrument sales of 1,212 units, up 37% over last year's comparable quarter. -- Gross profit of $18.3 million, up 21% over last year's comparable quarter.
SOURCE Abaxis, Inc.
